Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2025 | 1 | -$0.49 | -$0.49 | -$0.49 |
| Q2 2025 | 1 | -$0.46 | -$0.46 | -$0.46 |
| Q3 2025 | 1 | -$0.52 | -$0.52 | -$0.52 |
| Q4 2025 | 1 | -$0.40 | -$0.40 | -$0.40 |
| Q1 2026 | 1 | -$0.47 | -$0.47 | -$0.47 |
| Q2 2026 | 1 | -$0.47 | -$0.47 | -$0.47 |
| Q3 2026 | 1 | -$0.48 | -$0.48 | -$0.48 |
| Q4 2026 | 1 | -$0.42 | -$0.42 | -$0.42 |
| Q1 2027 | 1 | -$0.50 | -$0.50 | -$0.50 |
| Q2 2027 | 1 | -$0.57 | -$0.57 | -$0.57 |
| Q3 2027 | 1 | -$0.52 | -$0.52 | -$0.52 |
| Q4 2027 | 1 | -$0.46 | -$0.46 | -$0.46 |
NewAmsterdam Pharma Company N.V. last posted its earnings results on Wednesday, November 5th, 2025. The company reported $-0.7087 earnings per share for the quarter, missing analysts' consensus estimates of $-0.52484 by $0.18386. The company had revenue of 348.00 K for the quarter and had revenue of 45.56 M for the year. NewAmsterdam Pharma Company N.V. has generated $-3 earnings per share over the last year ($-2.56 diluted earnings per share) and currently has a price-to-earnings ratio of -18.98. NewAmsterdam Pharma Company N.V. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, November 17th, 2025 based on prior year's report dates.
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/05/2025 | Q3 2025 | -$0.52 | -$0.61 | -0.09 | $4.23 M | $348.00 K |
| 08/06/2025 | Q2 2025 | -$0.46 | -$0.15 | 0.31 | $3.49 M | $19.15 M |
| 05/08/2025 | Q1 2025 | -$0.49 | -$0.34 | 0.15 | N/A | $2.98 M |
| 02/26/2025 | Q4 2024 | -$0.49 | -$0.98 | -0.49 | N/A | $12.77 M |
| 11/06/2024 | Q3 2024 | -$0.50 | -$0.18 | 0.32 | $1.87 M | $29.11 M |
| 08/07/2024 | Q2 2024 | -$0.58 | -$0.38 | 0.2 | $1.21 M | $2.28 M |
| 05/08/2024 | Q1 2024 | -$0.62 | -$0.98 | -0.36 | N/A | $1.40 M |
| 02/28/2024 | Q4 2023 | N/A | -$0.52 | N/A | N/A | $803.00 K |
| 09/29/2023 | Q3 2023 | N/A | -$0.56 | N/A | N/A | $2.94 M |
| 08/07/2023 | Q2 2023 | N/A | -$0.43 | N/A | N/A | $1.72 M |
| 08/07/2023 | Q1 2023 | N/A | -$0.47 | N/A | N/A | $8.63 M |
| 03/31/2023 | Q4 2022 | N/A | -$2.20 | N/A | N/A | $5.50 M |
| 11/28/2022 | Q3 2022 | N/A | -$23.19 | N/A | N/A | $5.50 M |
| 06/29/2022 | Q2 2022 | N/A | $0.75 | N/A | N/A | $48.98 M |
| 03/29/2022 | Q1 2022 | N/A | $0.75 | N/A | N/A | $51.72 M |
| 12/30/2021 | Q4 2021 | N/A | -$1.73 | N/A | N/A | $0 |
| 09/29/2021 | Q3 2021 | N/A | -$0.82 | N/A | N/A | $0 |
| 06/29/2021 | Q2 2021 | N/A | -$0.43 | N/A | N/A | $0 |
| 03/30/2021 | Q1 2021 | N/A | -$0.43 | N/A | N/A | $0 |
| 12/30/2020 | Q4 2020 | N/A | $0.00 | N/A | N/A | $0 |
NewAmsterdam Pharma Company N.V. has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, November 17th, 2025 based offlast year's report dates.
The conference call for NewAmsterdam Pharma Company N.V.'s latest earnings report can be listened to online.
The conference call transcript for NewAmsterdam Pharma Company N.V.'s latest earnings report can be read online.
NewAmsterdam Pharma Company N.V. (:NAMSW) has a recorded annual revenue of $45.56 M.
NewAmsterdam Pharma Company N.V. (:NAMSW) has a recorded net income of $-241,598,000.NewAmsterdam Pharma Company N.V. has generated $-2.56 earnings per share over the last four quarters.
NewAmsterdam Pharma Company N.V. (:NAMSW) has a price-to-earnings ratio of -18.98 and price/earnings-to-growth ratio is 0.73.
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED